Influvac Sub-Unit (Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26), Influenza A/Vic)

The vaccine contains purified surface proteins from the targeted influenza strains. After injection, these antigens are processed by immune cells, which trigger a specific antibody response. The generated antibodies recognize and neutralise the corresponding influenza viruses, providing protective immunity if the person is later exposed to the virus.

The dose and schedule of Influvac Sub-Unit are determined by the prescribing healthcare professional based on age, health status, and local immunisation guidelines. The product is supplied as a single‑use injectable preparation, and the prescriber will specify the exact volume and route for each patient.

Safety data for Influvac Sub-Unit in pregnancy are limited. It may be administered during pregnancy only if the expected benefit to the mother outweighs any potential risk to the fetus. Breastfeeding is not a contraindication, but mothers should discuss vaccination with their healthcare provider to make an informed decision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Influvac Sub-Unit is a subunit vaccine that uses purified viral proteins rather than whole‑virus particles or live attenuated virus. This design can result in a lower reactogenicity profile compared with some inactivated or live‑attenuated vaccines, while still providing effective protection against the included A and B strains.

The vaccine must be stored refrigerated at 2‑8 °C. It should be kept in its original packaging to protect from light, must not be frozen, and should not be shaken. Prior to administration, inspect the vial for any particulate matter or discoloration and use within the recommended time after reconstitution, if applicable.

Influvac Sub-Unit is given by a single intramuscular or subcutaneous injection, typically into the deltoid muscle of the upper arm. The exact route, site and volume are determined by the prescribing clinician, following local immunisation protocols and the product’s prescribing information.

Serious adverse events, although rare, can include anaphylaxis, Guillain‑Barré syndrome, severe allergic reactions, high fever, seizures, and thrombocytopenia. Patients should be observed for a short period after vaccination and instructed to seek immediate medical attention if they experience symptoms such as difficulty breathing, swelling of the face or throat, or neurological changes.

Individuals with a known severe allergy to any component of the vaccine, including egg protein if present, should not receive Influvac Sub-Unit. It is also contraindicated for persons who have experienced a previous severe reaction to an influenza subunit vaccine. Children younger than six months of age are not eligible for this vaccine.